Fragile X syndrome (FXS) is caused by the full mutation (>200 CGG repeats) in the Fragile X Mental Retardation 1 (FMR1) gene. It is the most common inherited cause of intellectual disability (ID) and autism. This review focuses on neuropsychiatric disorders frequently experienced by premutation carriers with 55 to 200 CGG repeats and the pathophysiology involves elevated FMR1 mRNA levels, which is different from the absence or deficiency of fragile X mental retardation protein (FMRP) seen in FXS. Neuropsychiatric disorders are the most common problems associated with the premutation, and they affect approximately 50% of individuals with 55 to 200 CGG repeats in the FMR1 gene. Neuropsychiatric disorders in children with the premutation include anxiety, ADHD, social deficits, or autism spectrum disorders (ASD). In adults with the premutation, anxiety and depression are the most common problems, although obsessive compulsive disorder, ADHD, and substance abuse are also common. These problems are often exacerbated by chronic fatigue, chronic pain, fibromyalgia, autoimmune disorders and sleep problems, which are also associated with the premutation. Here we review the clinical studies, neuropathology and molecular underpinnings of RNA toxicity associated with the premutation. We also propose the name Fragile X-associated Neuropsychiatric Disorders (FXAND) in an effort to promote research and the use of fragile X DNA testing to enhance recognition and treatment for these disorders.
We recommend a controlled trial of metformin in those with FXS. Metformin appears to be an effective treatment of obesity including those with the PWP in FXS. Our study suggests that metformin may also be a targeted treatment for improving behavior and language in children and adults with FXS.
Fragile X Syndrome (FXS) is the most common cause of inherited intellectual disability
with prevalence rates estimated to be 1:5,000 in males and 1:8,000 in females. The increase of
>200 Cytosine Guanine Guanine (CGG) repeats in the 5’ untranslated region of the Fragile X Mental
Retardation 1 (FMR1) gene results in transcriptional silencing on the FMR1 gene with a subsequent
reduction or absence of fragile X mental retardation protein (FMRP), an RNA binding protein
involved in the maturation and elimination of synapses. In addition to intellectual disability,
common features of FXS are behavioral problems, autism, language deficits and atypical physical
features. There are still no currently approved curative therapies for FXS, and clinical management
continues to focus on symptomatic treatment of comorbid behaviors and psychiatric problems.
Here we discuss several treatments that target the neurobiological pathway abnormal in FXS. These
medications are clinically available at present and the data suggest that these medications can be
helpful for those with FXS.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.